Patents by Inventor Kathleen A. Battista

Kathleen A. Battista has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
    Patent number: 8778956
    Abstract: The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: July 15, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kathleen Battista, Gilles Bignan, Peter J. Connolly, Allen B. Reitz, Tina Morgan Ross, Malcolm Scott, Steven A. Middleton, Michael Orsini
  • Substituted pyrimidinyl oxime kinase inhibitors
    Patent number: 8367825
    Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: February 5, 2013
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Xu Guozhang, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Kamachi, Steven A. Middleton, Kathleen A. Battista, Gilles C. Bignan
  • Substituted Pyrimidinyl Oxime Kinase Inhibitors
    Publication number: 20120157412
    Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Application
    Filed: February 28, 2012
    Publication date: June 21, 2012
    Inventors: Kathleen A. Battista, Gilles C. Bignan, Guozhang Xu, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Karnachi, Steven A. Middleton
  • Substituted pyrimidinyl oxime kinase inhibitors
    Patent number: 8153791
    Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Grant
    Filed: December 12, 2006
    Date of Patent: April 10, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Guozhang Xu, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Karnachi, Steven A. Middleton, Kathleen A. Battista, Gilles C. Bignan
  • 5-OXAZOLIDIN-2-ONE SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS
    Publication number: 20100076003
    Abstract: The present invention is directed to novel 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful in the treatment of disorders and conditions mediated by the ORL-1 receptor. The present invention is further directed to processes for the preparation of said derivatives, pharmaceutical compositions comprising said derivatives and methods for the treatment of ORL-1 mediated disorders and conditions.
    Type: Application
    Filed: June 5, 2009
    Publication date: March 25, 2010
    Inventors: Kathleen BATTISTA, Gilles Bignan, Peter J. Connolly, Tina Morgan Ross
  • 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
    Patent number: 7655670
    Abstract: The present invention is directed to novel 3-spirocyclic indolyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the ORL-1 receptor.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: February 2, 2010
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Kathleen A. Battista, Gilles C. Bignan, Peter J. Connolly, Jessica J. Liu, Steven A. Middleton, Michael J. Orsini
  • Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
    Patent number: 7582649
    Abstract: The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.
    Type: Grant
    Filed: October 4, 2005
    Date of Patent: September 1, 2009
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Kathleen Battista, Gilles Bignan, Peter J. Connolly, Allen B. Reitz, Tina Morgan Ross, Malcolm Scott, Steven A. Middleton, Michael Orsini
  • Thia-tetraazaacenaphthylene kinase inhibitors
    Patent number: 7579356
    Abstract: The present invention is directed to novel thia-tetraazaacenaphthylene compounds of Formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of ATP-protein kinase interactions.
    Type: Grant
    Filed: April 10, 2006
    Date of Patent: August 25, 2009
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kathleen A. Battista, Gilles C. Bignan, Peter J. Connolly, Stuart Hayden, Sigmond G. Johnson, Ronghui Lin, Niranjan B. Pandey, Mark T. Powell
  • HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS
    Publication number: 20090124614
    Abstract: The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.
    Type: Application
    Filed: December 3, 2008
    Publication date: May 14, 2009
    Inventors: Kathleen BATTISTA, Gilles BIGNAN, Peter J. CONNOLLY, Allen B. REITZ, Tina Morgan ROSS, Malcolm SCOTT, Steven A. MIDDLETON, Michael ORSINI
  • SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS
    Publication number: 20080108611
    Abstract: The present invention is directed to thienopyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Application
    Filed: January 10, 2007
    Publication date: May 8, 2008
    Inventors: Kathleen A. Battista, Gilles C. Bignan, Peter J. Connolly, Stuart L. Emanuel, Stuart Hayden, Sigmond G. Johnson, Ronghui Lin, Steven A. Middleton, Niranjan B. Pandey, Mark T. Powell
  • 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS
    Publication number: 20080015214
    Abstract: The present invention is directed to novel 3-piperidin-4-yl-indole derivatives of formula (I) and forms thereof, wherein X, R1, R2, R3, R4 and R5 are as herein defined, pharmaceutical compositions thereof and use as ORL-1 receptor modulators for treating, preventing or ameliorating ORL-1 receptor mediated disorders and conditions.
    Type: Application
    Filed: October 18, 2006
    Publication date: January 17, 2008
    Inventors: Gilles Bignan, Kathleen Battista, Peter Connolly, Jessica Liu, Steven Middleton, Michael Orsini, Allen Reitz
  • Thia-tetraazaacenaphthylene kinase inhibitors
    Publication number: 20070265264
    Abstract: The present invention is directed to novel thia-tetraazaacenaphthylene compounds of Formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of ATP-protein kinase interactions.
    Type: Application
    Filed: April 10, 2006
    Publication date: November 15, 2007
    Inventors: Kathleen Battista, Gilles Bignan, Peter Connolly, Stuart Hayden, Sigmond Johnson, Ronghui Lin, Niranjan Pandey, Mark Powell
  • Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
    Publication number: 20070112016
    Abstract: The present invention is directed to novel 3-spirocyclic indolyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the ORL-1 receptor.
    Type: Application
    Filed: May 25, 2006
    Publication date: May 17, 2007
    Inventors: Kathleen Battista, Gilles Bignan, Peter Connolly, Jessica Liu, Steven Middleton, Michael Orsini
  • Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders
    Patent number: 7081463
    Abstract: The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: July 25, 2006
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Kathleen Battista, Gilles Bignan, Peter J. Connolly, Allen B. Reitz, Tina Morgan Ross, Malcolm Scott, Steven A. Middleton, Michael Orsini
  • Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
    Publication number: 20060030577
    Abstract: The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.
    Type: Application
    Filed: October 4, 2005
    Publication date: February 9, 2006
    Inventors: Kathleen Battista, Gilles Bignan, Peter Connolly, Allen Reitz, Tina Ross, Malcolm Scott, Steven Middleton, Michael Orsini
  • Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders
    Publication number: 20040142955
    Abstract: The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.
    Type: Application
    Filed: September 5, 2003
    Publication date: July 22, 2004
    Inventors: Kathleen Battista, Gilles Bignan, Peter J. Connolly, Allen B. Reitz, Tina Morgan Ross, Malcolm Scott, Steven A. Middleton, Michael Orsini